And if there was a proper CFO these questions could be answered very easily. Analysts will not follow without numbers.
If it is going to be a filing for agnostic tissue at this moment in time that is good strategy. That belongs at the Chairman of the Board. Her other two seats if CEO and CFO should be given up. A CEO with seasoned biotech expertise in immunotherapy. Someone to reassure markets.
Market Data 
Markets 
AI
